Results 201 to 210 of about 4,886,955 (347)

New treatment for pyridoxine-dependent epilepsy due to ALDH7A1 deficiency: first proof-of-principle of upstream enzyme inhibition in the mouse. [PDF]

open access: yesBrain Commun
van Karnebeek CDM   +12 more
europepmc   +1 more source

Domain associated with zinc fingers‐containing NF90‐NF45 complex inhibits m6A modification of primary microRNA by suppressing METTL3/14 activity

open access: yesFEBS Open Bio, EarlyView.
NF90–NF45 functions as a negative regulator of methyltransferase‐like 3/14 (METTL3/14)‐mediated N6‐methyladenosine (m6A) modification on primary microRNAs (pri‐miRNAs). NF90–NF45 binds to anti‐oncogenic pri‐miRNAs and inhibits their m6A modification, thereby suppressing the biogenesis of anti‐oncogenic miRNAs.
Takuma Higuchi   +6 more
wiley   +1 more source

Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease.

open access: yesJournal of the American Society of Nephrology, 2016
Malte Lenders   +5 more
semanticscholar   +1 more source

Pioglitazone plus (−)‐epigallocatechin gallate: a novel approach to enhance osteogenic performance in aged bone marrow mesenchymal stem cells

open access: yesFEBS Open Bio, EarlyView.
Aged human bmMSCs are seeded in the scaffold. Osteoblastic induction can slightly increase cell's bone‐forming activity to produce bone‐like tissues, shown as the sporadic xylenol orange‐stained spots (the lower left image). Notably, pioglitazone plus EGCG co‐treatment dramatically increases cell's bone‐forming activity and bone‐like tissue production (
Ching‐Yun Chen   +6 more
wiley   +1 more source

Enzymes and Inhibitants [PDF]

open access: yesScientific American, 1912
openaire   +1 more source

Kallikrein inhibitors [PDF]

open access: yes, 1979
Fink, Edwin   +2 more
core   +1 more source

Angiotensin-converting-enzyme inhibition in stable coronary artery disease.

open access: yesNew England Journal of Medicine, 2004
E. Braunwald   +9 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy